Galera Therapeutics, Inc.
GRTX
$0.0235
-$0.0004-1.67%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.00M | 11.29M | 12.85M | 19.32M | 22.84M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.15M | 17.71M | 25.05M | 37.65M | 46.95M |
| Operating Income | -14.15M | -17.71M | -25.05M | -37.65M | -46.95M |
| Income Before Tax | -19.16M | -19.82M | -29.11M | -45.75M | -59.08M |
| Income Tax Expenses | -203.00K | -203.00K | -- | -- | -- |
| Earnings from Continuing Operations | -18.96 | -19.61 | -29.11 | -45.75 | -59.08 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.96M | -19.61M | -29.11M | -45.75M | -59.08M |
| EBIT | -14.15M | -17.71M | -25.05M | -37.65M | -46.95M |
| EBITDA | -14.13M | -17.47M | -24.81M | -37.40M | -46.69M |
| EPS Basic | -0.35 | -0.36 | -0.59 | -1.00 | -1.42 |
| Normalized Basic EPS | -0.15 | -0.20 | -0.34 | -0.59 | -0.86 |
| EPS Diluted | -0.35 | -0.36 | -0.59 | -1.00 | -1.42 |
| Normalized Diluted EPS | -0.15 | -0.20 | -0.34 | -0.59 | -0.86 |
| Average Basic Shares Outstanding | 218.53M | 217.56M | 208.65M | 197.17M | 177.98M |
| Average Diluted Shares Outstanding | 218.53M | 217.56M | 208.65M | 197.17M | 177.98M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |